Wockhardt Reports INR 91 Crore PBT in Q2 FY26 with Revenue Growth
Filing Summary
Wockhardt Limited announced its un-audited financial results for Q2 FY26, reporting a profit before tax of INR 91 crore, a significant turnaround from a loss of INR 109 crore in the previous quarter. Revenue for the quarter reached INR 782 crore, an increase from INR 738 crore in Q1 FY26. The company also highlighted a 58% growth in EBITDA, reaching INR 160 crore. Key developments include the submission of a New Drug Application to the US FDA for ZAYNICH and the launch of MIQNAF NAFITHROMYCIN in India. The company continues to expand its biotech operations and intellectual property portfolio.
Wockhardt Limited has released its un-audited financial results for the second quarter of the financial year 2025-26. The company reported a profit before tax of INR 91 crore, marking a recovery from a loss of INR 109 crore in the previous quarter. The revenue for Q2 FY26 was INR 782 crore, up from INR 738 crore in Q1 FY26. The company also achieved a 58% increase in EBITDA, which stood at INR 160 crore for the quarter.
The financial performance highlights include a total revenue of INR 782 crore for Q2 FY26, compared to INR 818 crore in Q2 FY25. The EBITDA before R&D expenses was INR 194 crore, with an EBITDA margin of 20.5%. The R&D expenditure was INR 34 crore, representing 4.4% of sales. The company reported a profit after tax of INR 82 crore, with a PAT margin of 10.5%.
Operationally, Wockhardt made significant progress in its pharmaceutical and biotech segments. The company submitted a New Drug Application to the US FDA for its novel antibacterial agent, ZAYNICH, intended for treating complicated urinary tract infections. Additionally, Wockhardt launched MIQNAF NAFITHROMYCIN in India, which has been included in clinical guidelines for treating community-acquired bacterial pneumonia.
In terms of timeline, the NDA for ZAYNICH was filed in September 2025. The company received a breakthrough medicines program designation from the Saudi FDA in July 2025. The manufacturing of ZAYNICH is being conducted by European CMOs, and the filing in India was completed in March 2025.
Wockhardt’s business operations span multiple regions, with the India business generating INR 172 crore in Q2 FY26. The UK business contributed INR 313 crore, while the Irish business reported INR 59 crore. The company also filed 7 patents during the quarter, bringing the total to 3285, and was granted 5 patents, increasing its holdings to 858.
The company continues to focus on expanding its biotech operations, which recorded revenue of INR 154 crore for the quarter. This represents a 42% growth compared to Q4 FY25. The company is advancing its leadership in the biotech diabetes segment, with new partnerships in emerging markets and plans to launch insulin analogs in upcoming quarters.
Wockhardt is a global pharmaceutical and biotech company with a focus on antibacterial drug discovery. It is the only company with USFDA QIDP status for six antibacterial discovery programs. The company operates in multiple countries, including the UK, Ireland, and India, with a significant portion of its revenue coming from international markets.